Observational analysis of antibody-functionalized lipid nanocarriers in cancer therapy indicates challenges in targeted delivery.
Despite remarkable advances in cancer therapeutics, conventional treatments still face significant hurdles, including systemic toxicity, poor tumor specificity, multidrug resistance, and suboptimal intracellular delivery.
No takes yet. Share an insight, caveat, or question.
Nabih et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: